论文部分内容阅读
目的研究黄芪多糖对糖尿病动脉粥样硬化的影响及可能机制。方法将60只大鼠分为模型组和对照组。模型组大鼠予腹腔注射链脲菌素造模,成模大鼠再随机分为黄芪多糖组和糖尿病组。黄芪多糖组每日注射黄芪多糖,糖尿病组给予高脂高糖饲料喂养。2个月后检测血脂、血小板内皮细胞黏附分子1(PECAM-1)、丙二醛(MDA)、超氧化物歧化酶(SOD)、血浆8-异前列腺素F2α(8-iso-PGF2α),光镜下观察主动脉病变。结果模型组大鼠的日均饮水量、体质量及空腹血糖显著高于对照组大鼠[(62.42±2.14)mL vs(44.42±2.12)mL、(368.24±5.23)g vs(281.42±3.21)g、(19.24±1.12)mmol·L~(-1)vs(4.76±0.42)mmol·L~(-1)](P<0.05)。黄芪多糖组的总胆固醇(TC)、低密度脂蛋白胆固醇LDL-L显著低于糖尿病组[(5.87±0.64)mmol·L~(-1)vs(15.32±0.76)mmol·L~(-1)、(4.54±0.43)mmol·L~(-1)vs(11.42±1.21)mmol·L~(-1)](P<0.05),2组的三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)比较差异无统计学意义(P>0.05)。黄芪多糖组内膜(17.02±1.34)μm厚于对照组(6.01±0.43)μm,但薄于糖尿病组(51.54±4.24)μm,差异均有统计学意义(P<0.05)。黄芪多糖组的MDA、8-iso-PGF2α、PECAM-1含量显著低于糖尿病组[(8.11±0.75)mmol·L~(-1)vs(9.03±0.79)mmol·L~(-1)、(73.56±6.43)vs(99.24±10.34)、(0.16±0.02)mmol·L~(-1)vs(0.19±0.05)mmol·L~(-1)](P<0.05),SOD含量显著高于糖尿病组[(213.34±8.98)k U·L~(-1)vs(172.45±6.44)k U·L~(-1)](P<0.05)。结论黄芪多糖治疗能减轻糖尿病动脉粥样硬化,所发挥的作用可能与抑制主动脉PECAM-1表达、抗氧化应激相关。
Objective To study the effect of astragalus polysaccharide on diabetic atherosclerosis and its possible mechanism. Methods 60 rats were divided into model group and control group. Rats in model group were injected intraperitoneally with streptozotocin. Rats in model group were randomly divided into astragalus polysaccharide group and diabetic group. Astragalus polysaccharides group daily injection of astragalus polysaccharide, diabetic group given high-fat, high-sugar feed. After 2 months, serum levels of PECAM-1, MDA, SOD, 8-iso-PGF2α, Aortic lesions were observed under light microscope. Results The average daily drinking water volume, body weight and fasting blood glucose in model group were significantly higher than those in control group [(62.42 ± 2.14) mL vs (44.42 ± 2.12) mL, (368.24 ± 5.23) g vs (281.42 ± 3.21) g, (19.24 ± 1.12) mmol·L -1 vs 4.76 ± 0.42 mmol·L -1] (P <0.05). The contents of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-L) in astragalus polysaccharide group were significantly lower than those in diabetic group [(5.87 ± 0.64) mmol·L -1 vs 15.32 ± 0.76 mmol·L -1 ), (4.54 ± 0.43) mmol·L -1 vs 11.42 ± 1.21 mmol·L -1] (P <0.05). The levels of triglyceride (TG), high density lipoprotein Cholesterol (HDL-C) was no significant difference (P> 0.05). The inner membrane of APS group (17.02 ± 1.34) μm thicker than the control group (6.01 ± 0.43) μm, but thinner than the diabetic group (51.54 ± 4.24) μm, the difference was statistically significant (P <0.05). The contents of MDA, 8-iso-PGF2α and PECAM-1 in Astragalus polysaccharide group were significantly lower than those in diabetic group [(8.11 ± 0.75) mmol·L -1 (9.03 ± 0.79) mmol·L -1, (73.56 ± 6.43) vs (99.24 ± 10.34) and (0.16 ± 0.02) mmol·L -1 vs 0.19 ± 0.05 mmol·L -1] (P <0.05) In the diabetic group [(213.34 ± 8.98) kU · L -1 vs (172.45 ± 6.44) kU · L -1] (P <0.05). Conclusion Astragalus polysaccharide can reduce atherosclerosis in diabetic rats, which may be related to the inhibition of aortic PECAM-1 expression and anti-oxidative stress.